Literature DB >> 21672479

A new dawn in prostate cancer management: Do we have the trials to support it?

D Andrew Loblaw1.   

Abstract

Entities:  

Year:  2011        PMID： 21672479      PMCID： PMC3114027          DOI： 10.5489/cuaj.11098

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  12 in total

1.  Androgen deprivation therapy for prostate cancer-review of indications in 2010.

Authors:  H Quon; D A Loblaw
Journal:  Curr Oncol       Date:  2010-09       Impact factor: 3.677

2.  Randomized study evaluating testosterone recovery using short-versus long-acting luteinizing hormone releasing hormone agonists.

Authors:  Howard Huaihan Pai; Tom Pickles; Mira Keyes; Stuart Jones; Rachel E McDonald; Mary Lesperance; Eric Berthelet
Journal:  Can Urol Assoc J       Date:  2011-06       Impact factor: 1.862

3.  Evaluation of radiobiologic biochemical control in a large permanent prostate brachytherapy population from a single institution using AAPM TG-137 parameters.

Authors:  Wayne M Butler; Renee R Stewart; Gregory S Merrick
Journal:  Brachytherapy       Date:  2010-02-11       Impact factor: 2.362

4.  Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment.

Authors:  P N Lara; R Higdon; N Lim; K Kwan; M Tanaka; D H Lau; T Wun; J Welborn; F J Meyers; S Christensen; R O'Donnell; C Richman; S A Scudder; J Tuscano; D R Gandara; K S Lam
Journal:  J Clin Oncol       Date:  2001-03-15       Impact factor: 44.544

5.  Comparison of health-related quality of life 5 years after SPIRIT: Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial.

Authors:  Juanita Mary Crook; Alfonso Gomez-Iturriaga; Kris Wallace; Clement Ma; Sharon Fung; Shabbir Alibhai; Michael Jewett; Neil Fleshner
Journal:  J Clin Oncol       Date:  2010-12-13       Impact factor: 44.544

6.  Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer.

Authors:  Thomas P Boike; Yair Lotan; L Chinsoo Cho; Jeffrey Brindle; Paul DeRose; Xian-Jin Xie; Jingsheng Yan; Ryan Foster; David Pistenmaa; Alida Perkins; Susan Cooley; Robert Timmerman
Journal:  J Clin Oncol       Date:  2011-04-04       Impact factor: 44.544

7.  Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy.

Authors:  Al V Taira; Gregory S Merrick; Wayne M Butler; Robert W Galbreath; Jonathan Lief; Edward Adamovich; Kent E Wallner
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-06-03       Impact factor: 7.038

8.  Brachytherapy or conformal external radiotherapy for prostate cancer: a single-institution matched-pair analysis.

Authors:  Tom Pickles; Mira Keyes; W James Morris
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-01-01       Impact factor: 7.038

9.  Phase I/II study of a five-fraction hypofractionated accelerated radiotherapy treatment for low-risk localised prostate cancer: early results of pHART3.

Authors:  C I Tang; D A Loblaw; P Cheung; L Holden; G Morton; P S Basran; R Tirona; M Cardoso; G Pang; S Gardner; A Cesta
Journal:  Clin Oncol (R Coll Radiol)       Date:  2008-10-05       Impact factor: 4.126

10.  Postoperative nomogram predicting the 9-year probability of prostate cancer recurrence after permanent prostate brachytherapy using radiation dose as a prognostic variable.

Authors:  Louis Potters; Mack Roach; Brian J Davis; Richard G Stock; Jay P Ciezki; Michael J Zelefsky; Nelson N Stone; Paul A Fearn; Changhong Yu; Katsuto Shinohara; Michael W Kattan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-06-18       Impact factor: 7.038
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.